Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
Psychology, Health & Medicine|July 2, 2019
Work engagement as a mediator between organizational commitment and job satisfaction among community health-care workers in China: a cross-sectional studyWei-Quan Lin, Le-Xin Yuan, Shi-Yuan Kuang, et al.
The Journal of International Medical Research|May 26, 2021
A novel prognostic model for angioimmunoblastic T-cell lymphoma: A retrospective study of 55 casesJie Sun, Sha He, Hong Cen, et al.
Zhonghua Wai Ke Za Zhi [Chinese Journal of Surgery]|October 5, 2013
[Total trans-oral endoscopic thyroidectomy and cervical lymphadenectomy: a human cadavers surgery study]Yuan-Hang Su, Zhi-Ping Tang, Zi-Hai Ding, et al.
Plos One|December 31, 2024
Correction: Long non-coding RNA SNHG17 may function as a competitive endogenous RNA in diffuse large B-cell lymphoma progression by sponging miR-34a-5pShengjuan Lu, Lin Zeng, Guojun Mo, et al.
Plos One|November 21, 2023
Long non-coding RNA SNHG17 may function as a competitive endogenous RNA in diffuse large B-cell lymphoma progression by sponging miR-34a-5pShengjuan Lu, Lin Zeng, Guojun Mo, et al.
Journal of Hematology & Oncology|October 10, 2021
CAR T cells targeting CD99 as an approach to eradicate T-cell acute lymphoblastic leukemia without normal blood cells toxicityJiangzhou Shi, Zijian Zhang, Hong Cen, et al.
Cancer|December 21, 2022
Bendamustine in the treatment of patients with indolent non-Hodgkin lymphoma refractory or relapse to rituximab treatment: An open-label, single-agent, multicenter study in ChinaYan Gao, Yizhen Liu, Yafei Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 30, 2023
Sugemalimab Monotherapy for Patients With Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (GEMSTONE-201): Results From a Single-Arm, Multicenter, Phase II StudyHuiqiang Huang, Rong Tao, Siguo Hao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2023
The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical TrialTingyu Wang, Xiuhua Sun, Lihua Qiu, et al.
Nature Communications|June 15, 2026
Liposomal mitoxantrone plus tislelizumab in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma: a phase 1b/2 trialQihua Zou, Shenrui Bai, Liang Wang, et al.
Pageof 6